JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

Intermittent fasting may benefit antioxidant and inflammatory markers in postmenopausal women with rheumatoid arthritis.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...